A new study in JAMA offers the first evidence on how Medicare’s WISeR pilot has affected patients’ use of care. Under the pilot, traditional Medicare requires prior authorization, with reviews conducted by contractors encouraged to use artificial intelligence. The study found an immediate drop in use of the targeted services.
WISeR, short for Wasteful and Inappropriate Service Reduction, launched Jan. 1, 2026, in Arizona, New Jersey, Ohio, Oklahoma, Texas and Washington. It is scheduled to run six years. It requires approval in advance for a set of services the government considers vulnerable to fraud, waste and abuse. Traditional Medicare had historically almost never required prior authorization. The companies doing the reviews are mostly technology firms, according to the University of Minnesota School of Public Health (opens in new tab).
Researchers from Minnesota and Brown University used Epic Cosmos, an electronic health record dataset covering more than 300 million patient records. They compared monthly use of targeted services among traditional Medicare patients in the six states with use in all other states and the District of Columbia, over the two years before launch and the first six months after. Encounters for epidural steroid injections, the highest-volume service in the model, fell 15.0% relative to baseline. Other targeted services fell 19.5%, according to the JAMA summary.
Services that were slated for WISeR but never brought in did not change, which the authors say supports the conclusion that prior authorization drove the decline. The effect faded over time. For epidural steroid injections, the reduction shrank from about 21% in the first quarter to about 9% in the second. For other services, it went from 21% to 18%.
“The key question we can’t yet answer is whether the care not received was wasteful or necessary,” said lead author Hannah Neprash, an associate professor at Minnesota. Co-author Michael Barnett of Brown said, “As a physician, I know how burdensome prior authorization can be,” and added that early results suggest “doctors may be adapting rapidly to the new system.”
The pilot has been contentious. An earlier KFF (opens in new tab) analysis noted that vendors can receive a share of savings from denied services, and that policymakers have raised concerns that this creates an incentive to deny care. According to KFF (opens in new tab), CMS has said vendors must get a second opinion from a human clinician before issuing an AI-based denial.